These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 18984024)

  • 1. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity.
    Bongfen SE; Ntsama PM; Offner S; Smith T; Felger I; Tanner M; Alonso P; Nebie I; Romero JF; Silvie O; Torgler R; Corradin G
    Vaccine; 2009 Jan; 27(2):328-35. PubMed ID: 18984024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognition of different domains of the Plasmodium falciparum CS protein by the sera of naturally infected individuals compared with those of sporozoite-immunized volunteers.
    Calle JM; Nardin EH; Clavijo P; Boudin C; Stüber D; Takacs B; Nussenzweig RS; Cochrane AH
    J Immunol; 1992 Oct; 149(8):2695-701. PubMed ID: 1401909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei.
    Bergmann-Leitner ES; Duncan EH; Leitner WW; Neutzner A; Savranskaya T; Angov E; Tsokos GC
    Vaccine; 2007 Nov; 25(45):7732-6. PubMed ID: 17931754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of two long synthetic merozoite surface protein 2 peptides as malaria vaccine candidates.
    Flueck C; Frank G; Smith T; Jafarshad A; Nebie I; Sirima SB; Olugbile S; Alonso P; Tanner M; Druilhe P; Felger I; Corradin G
    Vaccine; 2009 May; 27(20):2653-61. PubMed ID: 19428875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmodium falciparum CS C-terminal fragment: preclinical evaluation and phase I clinical studies.
    Roggero MA; Weilenmann C; Bonelo A; Audran R; Renggli J; Spertini F; Corradin G; López JA
    Parassitologia; 1999 Sep; 41(1-3):421-4. PubMed ID: 10697896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa.
    Dobaño C; Doolan DL
    Mol Immunol; 2007 Apr; 44(11):3037-48. PubMed ID: 17303242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria.
    Yadava A; Nurmukhambetova S; Pichugin AV; Lumsden JM
    J Infect Dis; 2012 May; 205(9):1456-63. PubMed ID: 22457289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic polypeptides corresponding to the non-repeat regions from the circumsporozoite protein of Plasmodium falciparum: recognition by human T-cells and immunogenicity in owl monkeys.
    López JA; González JM; Kettner A; Arévalo-Herrera M; Herrera S; Corradin G; Roggero MA
    Ann Trop Med Parasitol; 1997 Apr; 91(3):253-65. PubMed ID: 9229019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.
    Hermsen CC; Verhage DF; Telgt DS; Teelen K; Bousema JT; Roestenberg M; Bolad A; Berzins K; Corradin G; Leroy O; Theisen M; Sauerwein RW
    Vaccine; 2007 Apr; 25(15):2930-40. PubMed ID: 16914240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites.
    Meraldi V; Romero JF; Kensil C; Corradin G
    Vaccine; 2005 Apr; 23(21):2801-12. PubMed ID: 15780728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cellular and humoral responses to recombinant protein and synthetic peptides of exon2 region of Plasmodium falciparum erythrocyte membrane protein1 (PfEMP1) among malaria patients from an endemic region.
    Das P; Grewal JS; Mahajan B; Chauhan VS
    Parasitol Int; 2007 Mar; 56(1):51-9. PubMed ID: 17258500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody response profiles induced by Plasmodium falciparum glutamate-rich protein in naturally exposed individuals from a Brazilian area endemic for malaria.
    Pratt-Riccio LR; Lima-Junior JC; Carvalho LJ; Theisen M; Espíndola-Mendes EC; Santos F; Oliveira-Ferreira J; Goldberg AC; Daniel-Ribeiro CT; Banic DM
    Am J Trop Med Hyg; 2005 Dec; 73(6):1096-103. PubMed ID: 16354819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
    Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
    Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restricted T-cell epitope diversity in the circumsporozoite protein from Plasmodium falciparum populations prevalent in Iran.
    Zakeri S; Avazalipoor M; Mehrizi AA; Djadid ND; Snounou G
    Am J Trop Med Hyg; 2007 Jun; 76(6):1046-51. PubMed ID: 17556609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2.
    Saul A; Lord R; Jones GL; Spencer L
    J Immunol; 1992 Jan; 148(1):208-11. PubMed ID: 1727867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design.
    Singh S; Soe S; Mejia JP; Roussilhon C; Theisen M; Corradin G; Druilhe P
    J Infect Dis; 2004 Sep; 190(5):1010-8. PubMed ID: 15295710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do antibody responses to malaria vaccine candidates influenced by the level of malaria transmission protect from malaria?
    Nebie I; Tiono AB; Diallo DA; Samandoulougou S; Diarra A; Konate AT; Cuzin-Ouattara N; Theisen M; Corradin G; Cousens S; Ouattara AS; Ilboudo-Sanogo E; Sirima BS
    Trop Med Int Health; 2008 Feb; 13(2):229-37. PubMed ID: 18304269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging rules for subunit-based, multiantigenic, multistage chemically synthesized vaccines.
    Patarroyo ME; Patarroyo MA
    Acc Chem Res; 2008 Mar; 41(3):377-86. PubMed ID: 18266328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malaria vaccine: a current perspective.
    Sharma S; Pathak S
    J Vector Borne Dis; 2008 Mar; 45(1):1-20. PubMed ID: 18399312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.